Book a meeting
DO-BO

Remo Christen – Early paid access in Switzerland – Switzerland, wonderland? (Repost)

In this Podcast episode, Dr. Stefan Walzer is discussing the specifics of the Swiss market access & reimbursement including the famous article 71, which allows an early paid access.

Who else could better speak about the Swiss system with him than Remo Christen? Remo is working since > 20 years in the Swiss market access environment in a leading role at Roche’s Swiss affiliate.

In this episode, listeners will learn the specifics of the Swiss culture, the reimbursement process also in comparison to the German AMNOG and why Switzerland is attractive for drug launches.

Related

How Do You Build a High-Performing Team in Pharma, Dr. Maurice Kléber?

By

Stefan Walzer

In this episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Dr. Maurice Kléber to explore what building a winning team really takes — drawing on 18 years of leadership and a shared love of ice hockey. They discuss why trust and psychological safety are the foundation of any high-performing […]

Where Does AI Really Add Value in Market Access, Dr. Seye Abogunrin?

By

Stefan Walzer

Everyone wants AI to click the button for them — the real question is whether you still need to click it at all. In this episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Dr. Seye Abogunrin, a health economist at Roche, Switzerland, to move AI in market access from […]

Why Should Early Health Economics Move Upstream, Dr. Björn Schwander & Julie Frappier?

By

Stefan Walzer

By the time most health economists get pulled in, the recipe is already set. In this episode of MAP — the Market Access Podcast, Dr. Stefan Walzer sits down with two industry veterans — Dr. Björn Schwander, Founder of AHEAD GmbH and a specialist in early health economic modeling, and Julie Frappier, senior health economist […]